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ABSTRACT
Objective To develop a tool for estimating national
trends in adult prevalence of sexually transmitted
infections by low- and middle-income countries, using
standardised, routinely collected programme indicator
data.
Methods The Spectrum-STI model ﬁts time trends in
the prevalence of active syphilis through logistic
regression on prevalence data from antenatal clinic-
based surveys, routine antenatal screening and general
population surveys where available, weighting data by
their national coverage and representativeness.
Gonorrhoea prevalence was ﬁtted as a moving average
on population surveys (from the country, neighbouring
countries and historic regional estimates), with trends
informed additionally by urethral discharge case reports,
where these were considered to have reasonably stable
completeness. Prevalence data were adjusted for
diagnostic test performance, high-risk populations not
sampled, urban/rural and male/female prevalence ratios,
using WHO’s assumptions from latest global and
regional-level estimations. Uncertainty intervals were
obtained by bootstrap resampling.
Results Estimated syphilis prevalence (in men and
women) declined from 1.9% (95% CI 1.1% to 3.4%) in
2000 to 1.5% (1.3% to 1.8%) in 2016 in Zimbabwe,
and from 1.5% (0.76% to 1.9%) to 0.55% (0.30% to
0.93%) in Morocco. At these time points, gonorrhoea
estimates for women aged 15–49 years were 2.5%
(95% CI 1.1% to 4.6%) and 3.8% (1.8% to 6.7%) in
Zimbabwe; and 0.6% (0.3% to 1.1%) and 0.36%
(0.1% to 1.0%) in Morocco, with male gonorrhoea
prevalences 14% lower than female prevalence.
Conclusions This epidemiological framework facilitates
data review, validation and strategic analysis,
prioritisation of data collection needs and surveillance
strengthening by national experts. We estimated ongoing
syphilis declines in both Zimbabwe and Morocco. For
gonorrhoea, time trends were less certain, lacking recent
population-based surveys.
INTRODUCTION
The global burden of sexually transmitted infec-
tions (STIs) continues to be high, with over 357
million new curable infections estimated in 2012,1
which result in high morbidity and mortality, infer-
tility, pregnancy and congenital complications, psy-
chosocial impacts and economic productivity
losses.2 3 At the national level, estimates of
population-based infection rates and trends in STIs
are important to guide speciﬁc control strategies,
programmes, advocacy and resource mobilisation.
Many countries have yet to implement STI surveil-
lance systems, and where these do exist the indica-
tor data produced vary. These challenges, and the
changing epidemiology of STIs, require new strat-
egies and technologies to expand and improve
disease surveillance at both country and global
levels.
Since 1995 the WHO has generated global and
regional STI prevalence estimates of four curable
STIs approximately every 5 years, using progres-
sively reﬁned epidemiological and statistical
methods.1 4 5 The most recent estimates, for 2012,
were based on a Bayesian meta-analytic analysis of
survey prevalence data of gonorrhoea, chlamydia
and trichomoniasis among low-risk populations,
and on national surveillance of syphilis seropreva-
lence among antenatal care (ANC) attendees.
Prevalence data were adjusted for laboratory test
types, and geography and age of study populations.
The precision and utility of these estimates are
limited by varying and uncertain data availability
and quality, as well as the representativeness of
survey samples. WHO also generated global and
regional incidence estimates from the prevalence
estimates, by adjusting for the average duration of
infection, which depends upon a number of addi-
tional factors which are very uncertain, such as
treatment-seeking behaviours, access to health ser-
vices and state of the epidemics.
WHO estimates did not include country-speciﬁc
estimates and, owing to changes in methods over
time, are not appropriate for generating time trends
(whether global or regional). To deal with these chal-
lenges, we have developed a country-level estimation
model, which is integrated into the Spectrum suite
of epidemiological estimation and health policy plan-
ning tools (http://www.avenirhealth.org/software-
spectrum.php). The Spectrum suite of programmes
has been developed to support estimation of
national burdens, trends, service needs and pro-
gramme impact for family planning, HIV/AIDS6–11
and, more recently, tuberculosis12 and malaria.13 14
The Spectrum-STI model currently focuses on
two STIs—active syphilis and gonorrhoea—in
adults. Active syphilis and gonorrhoea were chosen
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as they are the two STIs for which the 2016–2021 global health
sector strategy for STI control, adopted by the 69th World
Health Assembly, set impact goals.15 Also, these are the two
STIs for which countries routinely collect and annually report
indicator data, through the Global AIDS Response Progress
Reporting (GARPR) system to the Joint United Nations
Programme on HIV and AIDS (UNAIDS) and WHO.16–19
To develop the Spectrum estimation methodology, we initially
collated data from 10 countries to see what type of data were
readily available.20 Two of these countries were then chosen to
pilot the methodology in more detail—Zimbabwe and Morocco
—from which national STI experts joined the Spectrum-STI
development team.
This paper provides an overview of the Spectrum-STI
module, its data inputs and estimation method and assumptions,
and presents results for the two pilot countries. Estimate and
limitations related to input data and methodology are discussed,
and we make recommendations for strengthening STI surveil-
lance to facilitate and improve future estimations and evaluation
of trends.
METHODS
Overview
National prevalence estimates were generated from available
country data for syphilis, and for gonorrhoea supplemented by
data from neighbouring countries, using standard STI indica-
tors that most low- and middle-income countries collect and
report routinely: syphilis prevalence in pregnant women attend-
ing ANC from sentinel surveys/surveillance and routine pro-
grammatic screening, reported annually through the GARPR
system since 2009, and case report data on gonorrhoea and
urethral discharge (UD), reported through GARPR since 2013–
2014.16–18
Estimation used data from 1990–2015 as available, and result-
ing estimations covered the period 1995–2016. The method
ﬁrst estimates adult female prevalence, and then the correspond-
ing adult male prevalence.
The Spectrum-STI software is available at: http://
spectrumbeta.futuresinstitute.org/. For each country there is a
default database built-in, based on Avenir Health’s compilation
of data reported through GARPR and other prevalence survey
meta-analyses for both gonorrhoea and syphilis, as described
below, which the user can adapt, and use as a starting point to
create and update national estimations.
Syphilis prevalence
National syphilis estimates were generated for ‘probable
active’ infection, deﬁned as being concurrently rapid plasma
reagin (RPR)-positive and Treponema pallidum haemagglu-
tination assay (TPHA)-positive. This is the same deﬁnition
used by the WHO1 and the Institute of Health Metrics
and Evaluation21 22 in their regional and global syphilis
estimates.
A standardised database of the prevalence of syphilis in each
country was compiled with information from:
▸ Country reports of routine, continuous ANC screening
results, from health ministries into GARPR,19 for the
indicators:
– Coverage of routine syphilis screening among women pre-
senting for ﬁrst ANC visit (or, if ﬁrst visit not available,
any ANC visit), among pregnant women attending for
ﬁrst ANC visit, global data available at: http://apps.who.
int/gho/data/node.main.A1358STI?lang=en;
– The number of women screened for syphilis at ﬁrst ANC
visit (the denominator of the preceding indicator), global
data available at: http://apps.who.int/gho/data/node.main.
A1358STI?lang=en;
– Prevalence of syphilis among women screened at ﬁrst
ANC visit (or if ﬁrst visit not available, any ANC visit);
global data available at: http://apps.who.int/gho/data/node.
main.A1359STI?lang=en.
▸ Nationally representative syphilis prevalence surveys —that
is, sample-based surveillance among ANC women (ﬁrst-visit,
if available; otherwise any visit), typically done once every
2 years over a short (eg, 2 months) time period.
▸ All nationally or subnationally representative general popula-
tion prevalence surveys in non-ANC male and/or female
general populations, which met the criteria for representa-
tiveness and quality used in the WHO 2012 regional
estimations.1
All prevalence data points were adjusted for diagnostic test
performance: prevalence data based on combined RPR and
TPHA positivity were taken as such; those based on RPR only
were adjusted downward to 0.7-fold of the observed prevalence
for ANC and family planning populations; or to 0.6-fold for
other general populations; those based on TPHA only were
adjusted downward to 0.8-fold, those based on rapid
TPHA-based test in ANC populations to 0.7-fold; and data with
an unknown test to 0.75-fold the observed prevalence. This
adjustment was similar to that used in WHO global and regional
estimates.1 23 24 The test adjustment factors were chosen in con-
sultation with three international STI experts (Professor
Charlotte Gaydos, Professor Cesar Carcamo and Professor
Patricia Garcia, May 2016).
After the diagnostic test adjustment, the syphilis data were
adjusted upward by 10% to account for undersampling of
high-risk populations in general population surveys, as was
done by WHO in their regional and global estimates.1 In add-
ition, for those data points with 0% syphilis prevalence this
value was replaced by a prevalence calculated as 1 case divided
by 100 times the sample size, to allow for logistic regression
and generation of uncertainty intervals (see online
supplementary ﬁle 1). The sequence of these adjustments, as
applied for Zimbabwe and Morocco, is shown in online
supplementary ﬁle 2.
Each study was also assigned a weighting, to reﬂect its assumed
representativeness for the overall national ANC population in
the country:
▸ Nation-wide ANC surveys were assigned a weight of 100%,
to reﬂect their cluster-sampling design, ensuring representa-
tiveness. Data points with fewer than the maximum number
of sites were weighted downward proportionally by the rela-
tive number of sites, relative to the maximum number of
sites ever sampled for national representativeness (see online
supplementary ﬁle 2a, b).
▸ Routine ANC screening data were weighted according to the
coverage of the syphilis screening, as reported through
GARPR. This was done to account for the non-
representativeness of ‘routine’ data points, especially in the
past when coverage was still low.
▸ Non-ANC general population surveys were assigned a weight
of 50% if based on more than 20 sites nationwide, or
between 5% and 50% if based on fewer than 20 selected
sites (eg, for Morocco in 1999 and 2011–2012, online
supplementary ﬁle 2b). These are conservative weights, since
the representativeness of these data is less clear than for
ANC data.
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Estimating prevalence in ANC women
Once the database was constructed, logistic regressions were
performed with calendar year as independent variable. All data
were pooled —that is, we assumed there were no systematic
prevalence differences between ANC women and women in the
general adult population.1 Data were weighted as above and
then scaled by dividing by sample size, so that the sample size
did not inﬂuence the estimated prevalence level or trend but did
inﬂuence conﬁdence bounds.
For syphilis, we assumed that all qualifying data were repre-
sentative —that is, no adjustments were made for possible over-
sampling of urban or rural sites and urban/rural prevalence
differences.
CIs (ie, uncertainty ranges) were obtained using bootstrap
resampling (see online supplementary ﬁle 1).
Finally, the estimated point prevalence and the upper bound
of the 95% CI were restricted for any year before 1995–2021
in any country at a maximum of 20%, for both women and
men, based on empirical data from across low- and
middle-income countries since 1990.1 25
Estimating prevalence in adult women and men
The resulting estimated national prevalence trend for ANC
women was interpreted to also indicate prevalence and trends
for all women aged 15–49 years, as assumed in the WHO 2012
estimation.1 Furthermore, given a lack of prevalence data from
men in most countries, we assumed that prevalence in men aged
15–49 years nationwide equals the prevalence among women
attending ANC and adult women (as in WHO global estima-
tions1 4 5). This was substantiated by an average male-to-female
prevalence ratio found in patients with tuberculosis in sentinel
surveillance data from Morocco between 2005 and 2012 of, on
average, 1.06 for TPHA and 1.00 for RPR.26
Gonorrhoea prevalence
For gonorrhoea, the estimation method was based on the prin-
ciple that all of the—generally sparse—gonorrhoea prevalence
data from low-risk populations in a country, and the world
region in which that country is located, are informative and
should be used. However, studies that are more nationally repre-
sentative, and closer in time to the year(s) of interest, should get
a greater weight.
A database was compiled for each country drawing on gonor-
rhoea prevalence data identiﬁed through systematic reviews of
studies and surveys of low-risk general female and male popula-
tions, done for the WHO global and regional estimates in 2005,
2008 and 2012,1 supplemented by studies included in a
meta-analysis of gonorrhoea prevalence in ANC women in
sub-Saharan Africa25 and those from a meta-analysis of general
populations in the WHO Eastern Mediterranean region (Smolak
A, Mohamoud YA, Abu-Raddad LJ. The epidemiology of gonor-
rhea in the Middle East and North Africa: systematic review and
meta-analysis. 2016 (in preparation)). For each country the
database included studies from the country itself, studies
from bordering countries (https://en.wikipedia.org/wiki/List_of_
countries_and_territories_by_land_borders) and regional preva-
lence estimates for the subregion to which the country
belongs.1 25
Any additional studies that we became aware of, and that met
the inclusion criteria of the systematic reviews (Smolak et al (in
preparation)) 1 25 were also included. For studies that did not
specify the year of data collection, we assumed that the data
were collected 3 years before the publication date.
Observed prevalence was adjusted for diagnostic test perform-
ance, using the same approach as the 2012 WHO global and
regional estimates1 and other multisite meta-analyses:25 27
Test - Adjusted
Prevalence
¼ ðObserved Prevalenceþ Specificity 1Þ
Sensitivityþ Specificity 1 ð1Þ
Online supplementary ﬁle 3 provides information on the sensi-
tivities and speciﬁcities for each of the laboratory tests.
For the gonorrhoea estimation, male and female data were
combined. Male prevalence data were converted into a ‘data
point’ corresponding to that for women by applying a ﬁxed
0.86 male-to-female prevalence ratio, the same ratio as used in
the WHO global and regional estimations.1 4 5 Female ‘data
points’ thus inferred from male prevalence data (eg, for
Zimbabwe, from a rural population-based survey in 2001,
online supplementary ﬁle 228) were then merged to the female
prevalence dataset, using the original male sample size, and the
estimation method described below was applied to the com-
bined dataset, estimating the full prevalence time series for
women ﬁrst.
Studies conducted in exclusively rural or urban sites were
converted into a corresponding national prevalence, using
WHO’s approach to global and regional estimates, in which the
rural-to-urban gonorrhoea prevalence ratio was assumed to be
0.9.1 Weighting between rural and urban prevalences was based
on the country-year-speciﬁc proportion of urban population
according to the United Nations Population Division29 in that
year (in Zimbabwe, 32% throughout 1995–2016; in Morocco
increasing from 52% at 1995 to 60% at 2016).
To convert prevalence estimates for low-risk general popula-
tions to national overall prevalences, estimates were adjusted
upward by 10% to reﬂect the contribution of higher-risk popu-
lations, as was also done by the WHO in their regional and
global estimates.1 This seemed reasonable based on a recent
meta-analysis of gonorrhoea prevalence in Eastern
Mediterranean countries, where gonorrhoea prevalence in
female sex workers (FSW) was on average 10-fold higher than
that in women in the general population (Smolak et al (in prep-
aration)), and FSW were estimated to represent around 1% of
the total female adult population.30–33
In addition, all data points with a test-adjusted gonorrhoea
prevalence of 0 were replaced by a prevalence calculated as one
case divided by 100 times the sample size.
Each study was assigned a weight, based on whether it was a
prevalence study from the country itself (weight of 100%) or
from a neighbouring country (weight of 10%). In addition, we
included the latest regional estimate from the WHO (for the
region applicable), assigned a 1% weight.1 Also, for countries in
sub-Sahara Africa, regional estimates for either West/Central
Africa or East/Southern Africa were included for the period
1990–1999 put at 1996, and for 2000–2011 put at 2005,25
each at a 1% weight.
Estimating gonorrhoea prevalence in women
▸ The statistical estimation considered all eligible prevalence
studies at a given time t, in a ‘moving average’ approach (see
online supplementary ﬁle 1).
For countries with reliable national case reporting for either
laboratory-conﬁrmed gonorrhoea or syndromically diagnosed
cases of UD, in men, women, or both sexes combined, with at
least ﬁve data points of which one or more was after 2009,
national case reporting rates were used to inform the gonor-
rhoea prevalence trend ﬁtting. Case reports, however, were not
601Korenromp EL, et al. Sex Transm Infect 2017;93:599–606. doi:10.1136/sextrans-2016-052953
Original article
group.bmj.com on January 22, 2018 - Published by http://sti.bmj.com/Downloaded from 
used to inform the prevalence level, as case reporting is mostly
of unknown (even if stable) coverage and completeness. To this
end, the estimated gonorrhoea prevalence level was ‘anchored’
to an average prevalence as initially estimated from prevalence
studies (see online supplementary ﬁle 1)
Final estimates for women and men, and CIs
Gonorrhoea prevalence was assumed to be constant at the level
estimated for the latest year with a (country, neighbour or
regional) data point (country, neighbour or regional prevalence
study, or case report-based prevalence estimate; 2012 for both
Morocco and Zimbabwe) for all subsequent years. Similarly, we
assumed gonorrhoea prevalence to be constant at the level esti-
mated for the ﬁrst data point (1991 for Zimbabwe, 1999 for
Morocco) for all earlier years.
Prevalence estimates for adult men were generated from the
point estimates for women by applying the WHO’s estimated,
globally averaged male-to-female prevalence ratio of 0.86.1
Conﬁdence bounds were generated by bootstrapping (see online
supplementary ﬁle 1).
After the statistical estimation, we constrained the national
gonorrhoea point estimate of prevalence (and the upper bound
of the 95% CI) for any year (past, current and future) in any
country, to be at maximum 20% for women and 17% for men,
based on empirical data from across low- and middle-income
countries since 1990.1 25
RESULTS
Syphilis prevalence
For Zimbabwe, the estimation was based on data from seven
surveys conducted among women attending ANC between 2000
and 2012, and annual routine ANC programme data between
2008 and 2015 (ﬁgure 1 and online supplementary ﬁle 2a).
Estimated syphilis prevalence (equal in women and men 15–
49 years) declined from 1.9% (95% CI 1.1% to 3.4%) to 1.5%
(1.3% to 1.8%) between 2000 and 2016.
For Morocco, data from ANC surveys (10 years over
1996−2012) and two small-scale surveys among women attending
family planning clinics in 1999 and 2011−2012 both suggested a
declining prevalence (ﬁgure 1 and online supplementary ﬁle 2b).
Estimated syphilis prevalence declined from 1.5% (0.76–1.9%) to
0.55% (0.3–0.93%) between 2000 and 2016.
For both countries, the prevalence estimates were most precise
around 2005–2008, the mid-point of calendar years with data.
Gonorrhoea prevalence
For Zimbabwe, the estimation was based on prevalence surveys
conducted in the country in 1999, 2000 and 2001, surveys in
neighbouring countries Mozambique, Zambia, South Africa and
Botswana conducted between 1991 and 2011, and three
regional estimates (see online supplementary ﬁle 2c and ﬁgure
2A). Spectrum estimated a stable gonorrhoea prevalence in
women of around 2.5% (1.1% to 4.6%) over 1995–2000, fol-
lowed by a slight rise from 2001, to 3.8% (1.8% to 6.7%) over
2012–2016, close to WHO’s regional estimate for Southern
Africa1(ﬁgure 2). Corresponding estimates for men, based on an
assumed male-to-female prevalence ratio (see ‘Methods’) were
2.2% (1.0% to 3.9%) at 2000 and 3.3% (1.5% to 5.7%) at
2016. Reports of patients with UD were available, but not
judged of sufﬁciently stable coverage and completeness over
time, to inform prevalence time trends.
For Morocco, data were used from national surveys in
women attending ANC and family planning clinics in 1999 and
2011–2012 (see online supplementary ﬁle 2d and ﬁgure 2B).
No qualifying studies were identiﬁed from any of the countries
neighbouring Morocco. During on-site workshops with national
experts and stakeholders held in May and September 2016,
Ministry of Health representatives decided to consider Egypt as
a proxy neighbouring country, in view of its similar sociobeha-
vioural and STI healthcare situation. One survey from Egypt,
conducted among women attending ANC and family planning
clinics in 1999–2000, was included in the estimation. In addi-
tion, annual UD case reporting rates over 2000–2015, the
period since introduction of the syndromic STI treatment
approach in Morocco, were used to inform the gonorrhoea
prevalence trend.
Spectrum estimated a stable gonorrhoea prevalence in women
over 1995–1999 to 0.6% (0.3% to 1.1%) in year 2000, fol-
lowed by slight decline over 1999–2011. For the period 2012–
2016 the estimated female prevalence of 0.36% (0.1% to 1.0%)
was somewhat below the WHO’s estimate for the Eastern
Mediterranean region (0.62%).1 Corresponding estimates for
men were 0.53% (0.3% to 0.96%) at 2000 and 0.32% (0.12%
to 0.87%) at 2016.
Figure 1 Spectrum-estimated national adult syphilis prevalences. Data are shown after adjustments for diagnostic test performance and missing
high-risk populations, as described in the ‘Methods’ section. Regional estimates—shown for reference, but not used in the estimation process—are
those by WHO for 20121 for both countries, and those from a meta-analysis of antenatal care (ANC) surveys in sub-Sahara African countries for
1990–1999 (put at 1996) and 2000–2011 (put at 2005) for Zimbabwe.25 Dashed lines represent 95% CIs around the Spectrum estimate. Data
shown are for women aged 15–49 years; the estimated prevalence applies to both women and men 15–49 years.
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Sensitivity analysis
The principal drivers and uncertainties in estimated prevalence
levels and trends were evaluated in univariate sensitivity ana-
lysis, varying in turn, diagnostic adjustment factors, weights
applied to different types of data and the assumed annual dilu-
tion factor used in the moving-average trend estimation for
gonorrhoea.
For syphilis, in Morocco, the diagnostic test adjustments for
both RPR and TPHA, each used in about half of data points,
inﬂuenced prevalence level, at 2016 in a range from 0.36% to
0.74%, whereas the estimated trend of decline was robust across
all diagnostic assumptions evaluated (table 1a).
For Zimbabwe, the adjustment values for rapid test and RPR,
used in routine programmatic screening between 2008 and
2015, were critical. The estimated syphilis point prevalence at
2016 decreased (from default 1.54%) to 1.34–1.38% when
assuming only 45% sensitivity for either test; whereas preva-
lence increased to 1.96–1.99% when assuming 100% sensitivity
for either test. Furthermore, the estimated trend reversed into a
time-constant value if the rapid syphilis test was assumed to be
100% sensitive, or into a slight increase over 2000–2016
(instead of the default: slight decline) if RPR was assumed 100%
sensitive. The adjustment value for TPHA did not inﬂuence
Zimbabwe’s syphilis level at 2016 or the (declining) time trend.
Gonorrhoea prevalence estimates were sensitive to the speciﬁ-
city of diagnostic techniques that employed PCR and ligase
chain reaction (LCR), the most commonly used diagnostic tests:
if their speciﬁcity was varied between 99.0% and 100%, the
estimated prevalence in Morocco at 2016 shifted in a range
from 0.64% to 0.05% (table 1b). Across all alternative assump-
tions tested, the estimated slight decline from 2000 to 2016 was
maintained for Morocco, except when reducing the annual dilu-
tion factor to zero, which (by deﬁnition) resulted in a time-
constant prevalence estimate. For Morocco, giving more weight
to regional neighbour Egypt, with two relatively high prevalence
data points, increased the 2016 prevalence estimate from the
best estimate of 0.36–0.43%.
For Zimbabwe, similarly, the estimated gonorrhoea time trend
(of increasing prevalence) was maintained across all alternative
model assumptions, except when reducing the annual dilution
factor to zero. The point prevalence at 2016 increased (from
default 3.8%, up to 4.1%) when assuming lower speciﬁcity of
PCR and LCR tests (99.0% instead of default 99.7%), and
prevalence decreased (to 3.6%) when assuming 100% specif-
icity of PCR and LCR. Above all, Zimbabwe’s gonorrhoea preva-
lence at 2016 was sensitive to the weight given to neighbouring
country studies, increasing (to 4.5%) when weighting
neighbouring-country data each 30% (instead of default 10%) or
decreasing to 2.5% when not using neighbouring-country data.
DISCUSSION
The Spectrum-STI module is a tool that countries can use to
collate STI surveillance data and interpret temporal trends in
STI prevalence. Presented results for Zimbabwe and Morocco
reﬂect collaborations with national experts and show that, even
when data are limited, it is possible to make national trend esti-
mations. In addition, the process of collating and interpreting
the data systematically encourages programmes to identify key
data gaps, and to prioritise actions for improving surveillance
and for more strategic use of data and estimations.
In both countries, there were considerably more data for
syphilis than for gonorrhoea and therefore the syphilis estimates
are more robust. Results suggest an ongoing decline in the
prevalence of adult syphilis in both countries, consistent with
recent WHO estimates of syphilis trends in ANC women in
Africa,24 and as aimed for by programmes for the elimination of
congenital syphilis.34
Evidence is weaker for recent trends in gonorrhoea, which
has fewer population-based data than syphilis. For Morocco, the
slight decline in prevalence over 2002–2014 may be consistent
with an increase in formal treatment seeking for urethral and
vaginal discharge, as measured between two knowledge, attitude
and practice surveys among 15–24-year-old men and women in
2007 and 2013.35 36 The Spectrum-estimated decline is also
consistent with a decline since 2001 in HIV incidence and
increasing condom usage following expansion of Morocco’s
HIV response.33 37 Furthermore, gonorrhoea prevalence among
women consulting clinics for vaginal discharge and/or lower
abdominal pain, fell from 4.8% in 199638 39 to 1.0% in
2007,40 although the data from this selected population in
selected cities were not formally used in the estimation.
The higher syphilis and gonorrhoea prevalence estimates for
Zimbabwe compared with Morocco are consistent with
Zimbabwe’s much larger HIV epidemic. In Zimbabwe the
Figure 2 Spectrum-estimated national gonorrhoea prevalence in women aged 15–49 years. Data are shown after adjustments for diagnostic test
performance, urban versus rural prevalence ratios and missing high-risk populations, as described in the ‘Methods’ section. Regional estimates
(included in the estimation at a weight of 1% relative to national studies) are from the WHO for 2012,1 and for Zimbabwe from a meta-analysis of
antenatal care (ANC) surveys in sub-Sahara African countries for 1990–1999 (put at 1996) and 2000–2011 (put at 2005).25 Data and estimates
shown are for women 15–49 years; for Zimbabwe, some additional data included in the estimation are not shown in the graph: three male survey
data points from Zimbabwe; one male survey data point from South Africa; and 1 female data point from Mozambique in year 2000 at 26.8%
test-adjusted prevalence; see online supplementary ﬁle 2c).
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Spectrum model estimated a slight increase in the prevalence of
gonorrhoea between 2000 and 2010, and while syphilis preva-
lence decreased between 1995 and 2016 this decline was less
precipitous than in estimates for the Southern Africa region as a
whole25 (ﬁgure 1A) or for Morocco (ﬁgure 1B). It remains
unclear whether the estimated rise in gonorrhoea prevalence in
Zimbabwe is a true rise; the rise in prevalence from 1995 to
2016 estimated by Spectrum might have followed a decrease
over the years just before 1995. Both gonorrhoea and syphilis
might have fallen in the early 1990s (from higher levels in the
1980s), in conjunction with the reversal and fall of HIV inci-
dence after its peak around 1990,41 42 attributed to an increase
in condom usage and other behavioural risk reductions in the
early 1990s.43–46
The stronger evidence for a decline in syphilis compared with
that in gonorrhoea in Morocco and Zimbabwe, as well as
observed syphilis declines in ANC populations in the context of
programmes of congenital syphilis elimination globally,34
suggest that WHO’s global STI strategy target of a 90% reduc-
tion in infection incidence is probably more feasible for syphilis
than for gonorrhoea. This reﬂects the different natural histories,
and response to treatment and prevention interventions between
these infections, with notably a higher proportion of syphilis
cases being symptomatic1 47 48 and the emerging impact of
routine ANC syphilis screening being rolled-out.34 Also the
widespread use of syndromic management of genital ulcer
disease with benzathine penicillin has probably contributed to
declining syphilis rates, especially in high-HIV countries in
Southern and Eastern Africa, including Zimbabwe,49 whereas
the effectiveness and impact of gonorrhoea treatment may be
diminishing in some countries owing to rising microbial resist-
ance against some ﬁrst-line treatments.50
Limitations and next steps
The biggest challenge when using a data-driven model like
Spectrum is the quantity, quality and representativeness of data
available for use.
For gonorrhoea, burden estimation would be facilitated by
more frequent prevalence surveys—but with many competing
health and surveillance priorities this is unlikely to happen.
Improved, standardised gonorrhoea and UD case reporting,
with ongoing monitoring of healthcare access, coverage and
reporting completeness and STI aetiologies (eg, Rietmeijer51),
will strengthen the estimation of trends. However, given time-
varying, sometimes high but unknown extents of asymptomatic
gonorrhoea, this approach is not a good basis for inferring
prevalence levels even in countries with high STI treatment
coverage and reporting completeness. Future reﬁned methods
Table 1 Sensitivity analysis—effect of varying (selected) assumptions and values, on national prevalence estimates for adults aged 15–
49 years at years 2000 and 2016: (a) syphilis; (b) gonorrhoea
Parameter
Default
value
Alternative
assumption Prevalence Zimbabwe,
women, at 2000→2016
Prevalence Morocco,
women,at 2000→2016Lower Upper
(a) Syphilis
Default best syphilis prevalence estimates 1.94→1.54% 1.48%→0.55%
Diagnostic test performance, relative to RPR-positive plus TPHA-positive (dual positivity) as ‘gold standard’
TPHA in ANC or FP population 0.8 0.6 1.0 Lower value: 1.73→1.58%
Upper value: 2.11→1.49%
Lower value: 1.45→0.36%
Upper value: 1.57→0.74%
RPR 0.6 0.45 1.0 Lower value: 1.99→1.38%
Upper value: 1.84→1.99%
Lower value: 1.22→0.58%
Upper value: 2.27→0.46%
Rapid syphilis test (TPHA-based) 0.7 0.55 1.0 Lower value: 1.90→1.34%
Upper value: 1.96→1.96%
Not used
(b) Gonorrhoea
Default best gonorrhoea prevalence estimates 2.5→3.8% 0.60→0.36%
Diagnostic test performance—gonorrhoea
Specificity PCR and LCR for gonorrhoea, women, genital fluid 99.7% 99.0% 100% Lower value: 2.3→3.6%
Upper value: 2.7→4.0%
Lower value: 0.28→0.11%
Upper value: 0.67→0.55%
Specificity PCR, LCR and SDA for gonorrhoea, women, urine 99.7% 99.0% 100% Lower value: 2.3→3.7%
Upper value: 2.7→4.0%
Lower value:0.16→0.09%
Upper value:0.82→0.44%
Specificity PCR, LCR and SDA for gonorrhoea, women, urine and
genital fluid
99.7 99.0% 100% Lower value: 2.1→3.6%
Upper value: 2.8→4.1%
Lower value: 0.11→0.05%
Upper value:0.88→0.64%
Sensitivity of PCR/LCR and SDA for gonorrhoea, women, urine and
genital fluid
93.3%;
91.6%;
91.6%
80% 100% Lower value: 2.8→4.3%
Upper value: 2.4→3.6%
Lower value:0.67→0.41%
Upper value:0.54→0.32%
Sensitivity of culture for gonorrhoea, women 75.7% 50% 90% Lower value: 2.7→4.1%
Upper value: 2.6→3.8%
Not used
Other parameters in the gonorrhoea prevalence estimation
Weight of UD case report data points, relative to national prevalence
studies (the latter at 100%)
25% 1% 50% Not used Lower value: 0.70→0.26%
Upper value: 0.54→0.37%
Weight of neighbouring country prevalence surveys, relative to
national prevalence studies
10% 0% 30% Lower value: 2.2→2.5%
Upper value: 3.1→4.5%
Lower value: 0.43→0.31%
Upper value:0.82→0.43%
Annual dilution factor in moving average estimation for gonorrhoea* 20% 0% 40% Lower value: 3.0% constant
Upper value: 2.4→6.0%
Lower value: 0.49% constant
Upper value: 0.67→0.37%
*The annual dilution factor weights the contribution of each data point to the estimation for other years than the study year (earlier and later, within the period from first to last data
point) downward, by a fixed proportion (default value: 20%) for each additional year away from the estimated year.
ANC, antenatal care; FP, family planning; LCR, ligase chain reaction; RPR, rapid plasma reagin; SDA, strand displacement amplification; TPHA, Treponema pallidum haemagglutination
assay; UD, urethral discharge.
604 Korenromp EL, et al. Sex Transm Infect 2017;93:599–606. doi:10.1136/sextrans-2016-052953
Original article
group.bmj.com on January 22, 2018 - Published by http://sti.bmj.com/Downloaded from 
might rather try to estimate burdens and trends in gonorrhoea
and chlamydia in tandem, as there are more abundant chla-
mydia prevalence data, including from adolescent populations
targeted by chlamydia screening programmes being expanded
(as recommended in the WHO’s global STI strategy 2016–
202115), while noting that these infections differ in natural
history and resulting epidemic dynamics, even if they share
underlying risk behaviours.
The ﬁxed 10% upward adjustment for high-risk populations
typically missing from population prevalence surveys is crude.
However, in Morocco the comparative prevalences of gonor-
rhoea and syphilis in FSW in 2007 and 201232 52 combined
with estimates of the number of FSW30 31 33 suggest that 10%
may be a reasonable adjustment value. In future Spectrum ver-
sions, we hope to incorporate syphilis prevalence data from key
risk groups such as FSW and men who have sex with men,
which many countries monitor periodically through integrated
bio-behavioural surveillance.32 53 54 This should improve the
estimation, given variation among countries in risk gradients
between these key groups and the general adult population, and
variation in sizes of populations at risk.
Although not presented here, case incidence rates have been
calculated for Morocco, Zimbabwe and other countries using
the Spectrum-STI tool. Such estimates are important for plan-
ning of health services and in evaluation of STI healthcare
access and reporting completeness. Case incidence is a key
outcome also at global level: the WHO global STI strategy
2016–2021 set its impact targets as a 90% incidence reduction
from 2018 to 2030 for gonorrhoea and syphilis.15 In addition,
there is interest in expanding the Spectrum model to estimate
national burdens of congenital syphilis,24 55 as recommended by
the WHO, applying the same ANC prevalence data and female
prevalence estimates already used in Spectrum. Also, trends in
STI-related complications such as Ophthalmia neonatorum, esti-
mated to occur in 2–48% of neonates born to mothers with
gonorrhoea, if not receiving ocular prophylaxis,56 could be
added to the next Spectrum version.
Age differentials within adult STI rates were ignored, but
could be added if forthcoming age-disaggregated prevalence
data suggested plausible age patterns.
In the longer term, estimates ideally would be made at pro-
vincial or district level. In some countries it may already be pos-
sible to generate temporal trends for syphilis in ANC women at
subnational level. Many high-HIV countries use the Spectrum
AIDS Incidence Model for province-level HIV/AIDS estima-
tions;9 57 a similar process could be envisioned for syphilis esti-
mation. In countries where syphilis rates vary considerably by
geography, the resulting estimates may more powerfully detect
any (upward or downward) time trends, compared with
national-level estimation, where trends may get obscured or con-
founded if survey sites and the balance between low-prevalence
and high-prevalence regions happened to change over time.
In conclusion, the new Spectrum-STI estimation method is a
promising tool to improve national estimates of STI prevalence
and trends over time. The model has been developed for easy use
by national surveillance experts, which should help to strengthen
STI surveillance, programme design, evaluation and advocacy
activities at county, regional and global levels. Spectrum-based
STI estimations may, in turn, inform surveillance and programme
planning for HIV/AIDS, and be the basis for a future tool to
evaluate STI programme impacts and cost-effectiveness.
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